Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
NCT00326417
Completed
The purpose of the current study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia transplanted with marrow from HLA-compatible unrelated donors. Specifically, the study will determine whether the addition of fludarabine to the conditioning regimen previously described by Deeg et al. will permit a reduction in the CY dose, to a point where sustained hematopoietic engraftment and survival are maintained (or improved), while the frequency of major r... Read More
Gender:
ALL
Ages:
65 years and below
Trial Updated:
10/13/2021
Locations: Phoenix Children's Hospital, Phoenix, Arizona +21 locations
Conditions: Anemia, Aplastic
Register for Updates
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
NCT03003676
Completed
This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unresectable melanoma progressing after PD1 blockade. The primary objective of the study is to determine the safety of sequential treatment with ONCOS-102 followed by pembrolizumab. The protocol aims to enroll patients into two cohorts: Part I: up to 12 patients will receive sequential treatment with ONCOS-102 followed by pembrolizumab. Part II: up to 12 patients will receive an ini... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2021
Locations: University of Maryland Comprehensive Cancer Center, Baltimore, Maryland +3 locations
Conditions: Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Register for Updates
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
NCT00630253
Completed
RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, before a donor stem cell transplant helps to remove the patient's cells to allow for the transplant cells to take and grow. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells can... Read More
Gender:
ALL
Ages:
59 years and below
Trial Updated:
10/08/2021
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Fanconi Anemia
Register for Updates
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
NCT02212574
Terminated
Participants enrolling on this study will receive standard of care chemotherapy for Wnt positive medulloblastoma without the radiation therapy or the weekly chemotherapy that is given during radiation therapy.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
10/08/2021
Locations: Phoenix Childrens Hospital Hematology/Oncology, Phoenix, Arizona +15 locations
Conditions: Medulloblastoma
Register for Updates
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02951819
Completed
The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), in previously untreated subjects, and in relapsed subjects with multiple myeloma, as defined by the International Myeloma Working Group (IMWG) criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2021
Locations: Not set, Mobile, Alabama +25 locations
Conditions: Multiple Myeloma
Register for Updates
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
NCT02018458
Completed
The primary objective of this study is to determine the safety and feasibility of combining cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy. The secondary objectives of this trial are to determine pathologic complete response rates; disease-free survival; to assess immune biomarkers of immunity (antigen-specific CD8+ T cell immunity and TH2 T cells) in breast cancer biopsy specimens and blood samples in patients receiving DC vaccinations; and to assess the feas... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
10/07/2021
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Breast Cancer
Register for Updates
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
NCT04162756
Approved For Marketing
The primary objectives of this study are: Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell lymphoma (MCL) until KTE-X19 is commercially available Cohort 2: To provide access to KTE-X19 for individuals with r/r MCL whose commercially manufactured product did not meet commercial release specification(s)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2021
Locations: Stanford Cancer Institute, Stanford, California +8 locations
Conditions: Relapse/Refractory Mantle Cell Lymphoma
Register for Updates
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
NCT00464646
Completed
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function. This study will evaluate: * How bevacizumab, given with chemotherapy, and then bevacizumab given with trastuzumab after surgery, will affect breast tumors * Side effects from adding bevacizumab to chemotherapy and trastuzumab * Whether adding bevacizumab to chemotherapy and trastuzumab for breast cancer will affect the heart * If receiving... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/04/2021
Locations: Clearview Cancer Institute- Huntsville, Huntsville, Alabama +35 locations
Conditions: Breast Cancer
Register for Updates
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
NCT01008150
Completed
FB-7 is a Phase II, multi-center randomized study of neratinib in combination with weekly paclitaxel with or without trastuzumab followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for women with HER2-positive locally advanced breast cancer. Patients in the control arm will receive neoadjuvant trastuzumab in combination with weekly paclitaxel followed by AC. The primary aim of the study is to determine the pathologic complete response (pCR) rate in breast and axillary nodes... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/04/2021
Locations: Loma Linda University Medical Center, Loma Linda, California +41 locations
Conditions: Breast Cancer
Register for Updates
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NCT01705691
Completed
NSABP FB-9 is a Phase II, multi-center, randomized study of eribulin or weekly paclitaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for women with HER2-negative, operable and locally advanced breast cancer (stage IIb and III). Patients in the control arm will receive neoadjuvant weekly paclitaxel (WP) followed by AC. The primary aim of the study is to determine the pathologic complete response (ypCR) in breast and axillary lymph nodes following completion of neoadj... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/04/2021
Locations: CCOP, Colorado Cancer Research Program, Inc., Denver, Colorado +19 locations
Conditions: Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
NCT02566993
Completed
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2021
Locations: Alabama Oncology, Birmingham, Alabama +159 locations
Conditions: Small-cell Lung Cancer
Register for Updates
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318
Completed
This phase II trial studies the combination of pembrolizumab, bevacizumab, and low dose oral cyclophosphamide in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Monoclonal antibodies, such as pembrolizumab and bevacizumab, may block tumor growth in different ways such as boosting your own immune system to find, recognize and kill tumor cells as well as by blocking the growth of new blood vessels necessary for tumor growth and nutrition. Drugs used in chemo... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/16/2021
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Register for Updates